Earnings Call Summary | Rockwell Medical(RMTI.US) Q1 2024 Earnings Conference
Earnings Call Summary | Rockwell Medical(RMTI.US) Q1 2024 Earnings Conference
The company revised its guidance for 2024, now expecting net sales for 2024 between $90 million and $94 million, and a gross profit between $13 million and $15 million.The following is a summary of the Rockwell Medical, Inc. (RMTI) Q1 2024 Earnings Call Transcript:
以下是罗克韦尔医疗公司（RMTI）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Rockwell Medical reported Q1 2024 net sales of $22.7 million, a record for quarterly concentrate product revenue, representing a 15% increase over Q1 2023 results.
Gross profit for Q1 2024 was $3.1 million, an 18% increase over the same period in 2023.
The company revised its guidance for 2024, now expecting net sales for 2024 between $90 million and $94 million, and a gross profit between $13 million and $15 million.
罗克韦尔医疗公布的2024年第一季度净销售额为2,270万美元，创下了浓缩产品季度收入的纪录，比2023年第一季度的业绩增长了15％。
2024年第一季度的毛利为310万美元，比2023年同期增长18％。
该公司修订了2024年的指导方针，现在预计2024年的净销售额在9000万美元至9400万美元之间，毛利润在1300万至1500万美元之间。
Business Progress:
业务进展：
After the Evoqua's hemodialysis concentrates business acquisition, Rockwell Medical adjusted its product pricing and saw an increase in customer interest from various health systems and dialysis centers both nationally and internationally.
They have also secured several expanded agreements both domestically and internationally and expect to achieve a gross margin of 20% by 2025 and beyond 25% by 2026.
收购Evoqua的血液透析浓缩液业务后，罗克韦尔医疗调整了产品定价，国内外各种医疗系统和透析中心的客户兴趣有所增加。
他们还签订了几项国内外扩大的协议，预计到2025年毛利率将达到20％，到2026年将超过25％。
More details: Rockwell Medical IR
更多详情： 罗克韦尔医疗红外线
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。